ArticleMedical image analysis2025
Aligning personalized biomarker trajectories onto a common time axis: a connectome-based ODE model for Tau-Amyloid beta dynamics.
Article in Medical image analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Abnormal tau and amyloid beta are two primary imaging biomarkers used to assist in the diagnosis of Alzheimer's disease (AD). Recent efforts have focused on developing mechanism-based biophysical models to explain the spatiotemporal dynamics of these biomarkers. In this study, we adopt a connectome-based ODE model to capture the dynamics of tau and amyloid beta (Aβ), aiming to predict personalized future values of these biomarkers. The ODE model includes diffusion, reaction, and clearance terms, and accounts for tau-Aβ interactions. Additionally, it assumes a sparse initial condition (IC) of abnormalities, based on the assumption of localized initiation. Besides tau and Aβ, brain atrophy is used as a marker of neurodegeneration. We discuss the mathematical model of atrophy integrated into the tau-Aβ model. A common limitation in popular models is the use of chronological age as the time axis, which prevents the unification of subject trajectories onto a common time scale and hinders comprehensive cohort analysis. To address this issue, we use a normalized disease age that relates chronological age to biomarker values. In the ODE model, we use the disease age to track time and the biomarker dynamics. Furthermore, our analysis of region-of-interest-wise tau-Aβ temporal correlation reveals that different regions of interest (ROIs) play distinct roles across various disease stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.